Biotech | December 08, 2025
Freenome strikes SPAC deal to go public in 2026
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
Freenome expects the combined company to receive approximately $330 million in proceeds at closing
_Logo_256_384.png){kind=logo}
The Vital Shape panels provide tiered assessments to detect obesity-related risks early
Takeda will pay Innovent US$1.2 billion upfront, including a US$100 million equity investment in Innovent
Valorum will advance the commercialization and distribution of Armlupeg in the United States
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
Peapod Bio’s proprietary technologies can efficiently identify inhibitors and binding molecules for virtually any target
Senores Pharmaceuticals is poised to accelerate its presence in the Asia-Pacific region
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
The partnership aims to combine TQx’s in vivo therapeutic expertise with Kytopen’s continuous flow transfection technology
Sommaplast’s portfolio includes closures, droppers, dispensers and dosing cups, supporting a broad range of oral dosing applications
Subscribe To Our Newsletter & Stay Updated
